KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype

0483740 - ÚMG 2018 RIV US eng J - Článek v odborném periodiku
Kašpárek, Petr - Ileninová, Zuzana - Žbodáková, Olga - Kanchev, Ivan - Benada, Oldřich - Chalupský, Karel - Brattsand, M. - Beck, Inken - Sedláček, Radislav
KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
PLoS Genetics. Roč. 13, č. 1 (2017), č. článku e1006566. ISSN 1553-7404. E-ISSN 1553-7404
Grant CEP: GA MŠMT(CZ) ED1.1.00/02.0109; GA MŠMT(CZ) LQ1604; GA MŠMT(CZ) LM2011032; GA MŠMT(CZ) LO1509
Institucionální podpora: RVO:68378050 ; RVO:61388971
Klíčová slova: corneum chymotryptic enzyme * serine-protease inhibitor * skin barrier function * mouse model * hair-follicle * subtilisin-a * lekti * kallikrein * expression * mice
Obor OECD: Microbiology
Impakt faktor: 5.540, rok: 2017

Netherton syndrome (NS) is a severe skin disease caused by the loss of protease inhibitor LEKTI, which leads to the dysregulation of epidermal proteases and severe skin-barrier defects. KLK5 was proposed as a major protease in NS pathology, however its inactivation is not sufficient to rescue the lethal phenotype of LEKTI-deficient mice. In this study, we further elucidated the in vivo roles of the epidermal proteases in NS using a set of mouse models individually or simultaneously deficient for KLK5 and KLK7 on the genetic background of a novel NS-mouse model. We show that although the ablation of KLK5 or KLK7 is not sufficient to rescue the lethal effect of LEKTI-deficiency simultaneous deficiency of both KLKs completely rescues the epidermal barrier and the postnatal lethality allowing mice to reach adulthood with fully functional skin and normal hair growth. We report that not only KLK5 but also KLK7 plays an important role in the inflammation and defective differentiation in NS and KLK7 activity is not solely dependent on activation by KLK5. Altogether, these findings show that unregulated activities of KLK5 and KLK7 are responsible for NS development and both proteases should become targets for NS therapy.
Trvalý link: http://hdl.handle.net/11104/0278944